Category:Nootropics/Cognitive enhancers

The nootropics, or cognitive enhancers, are the medicines and other materials taken in the hope of improving the workings of the mind: memory, attention, learning, mental stamina. The word was coined in 1972, from Greek roots meaning roughly "to turn the mind," for a specific and demanding pharmacological ideal. In the half-century since, it has escaped that ideal and spread across a wide and largely unregulated marketplace. The class the word now names is held together less by any shared chemistry, or any shared weight of evidence, than by a shared promise; and it is the class in which the distance between what is claimed and what has been shown is widest. Its one corner of firm ground, the medicines for the dementias, treats a disease, and treats it modestly; it does not enhance a healthy mind.

The class begins with one man and one molecule. In 1964, at the Belgian pharmaceutical company UCB, the Romanian-born psychologist and chemist Corneliu Giurgea synthesized a compound, piracetam, that he had expected to act as a mild sedative. It did not sedate. In testing it appeared instead to improve learning and memory, and to do so without the stimulation, the sedation, or the toxicity that accompanied the psychoactive medicines then known. Giurgea judged that he had found something genuinely new, and in 1972 he gave it a name: "nootropic," from the Greek nous, mind, and trepein, to turn.^[1]

Giurgea did not define the word loosely. A nootropic, in his account, was a substance that enhanced learning and memory; that protected the brain against physical or chemical injury; that improved the flow of information within the brain; and, the defining negative condition, that did all of this while lacking the sedative, the stimulant, and the toxic actions of the ordinary psychoactive medicines. It was a demanding definition, and piracetam itself, the founding example, has never been shown by the standard of modern evidence to meet it: a Cochrane review of piracetam for cognitive impairment and dementia found the evidence too poor, in both quality and quantity, to support its use.^[2]

From piracetam grew a chemical family, the racetams, all built on the same five-membered pyrrolidone ring: aniracetam, oxiracetam, pramiracetam, phenylpiracetam, coluracetam, and others. Several are licensed as medicines in Europe and in the former Soviet states; none is approved by the United States Food and Drug Administration, and in the United States they are sold, where they are sold at all, as unregulated supplements. This is the first appearance of a pattern that runs through the whole class: what counts as a nootropic, and whether it counts as a medicine at all, depends heavily on where one is standing.

Giurgea's word did not stay where he left it. In ordinary use today, "nootropic" names not a defined pharmacological class but an open and loosely bounded category: the racetams, but also caffeine, herbal extracts, prescription stimulants taken off-label, vitamins, and a continual churn of novel supplement compounds, most of them never tested to the standard Giurgea's own definition implied. Whether a reference work should hold the word to its strict original sense or follow its broad modern use is a genuine and unsettled question.

While the racetams gathered their uncertain following, a separate line of work was building the one part of this class that would come to stand on firm evidence. Through the 1970s and 1980s the study of Alzheimer's disease converged on a finding: the brains of people who had died with the disease showed a marked loss of the neurons that release acetylcholine, and the depth of that loss tracked the severity of the dementia. This was the cholinergic hypothesis, and it suggested a treatment, to raise the level of acetylcholine in the brain by blocking cholinesterase, the enzyme that breaks it down.^[3]

The first cholinesterase inhibitor licensed for Alzheimer's disease, tacrine, reached the market in 1993. It was a difficult medicine: it had to be taken four times a day, and it injured the liver in a large fraction of those who took it, and it is no longer used. But it established the principle, and better-tolerated successors followed within a few years, donepezil in the later 1990s, then rivastigmine and galantamine. These remain in use. A medicine of a different kind, memantine, was added in 2003: rather than raise acetylcholine, memantine blunts the overactivity of the glutamate NMDA receptor that is thought to contribute to the death of neurons, and it is used in the moderate and severe stages of the disease.^[4] None of these medicines halts the disease; each, at best, lifts cognition modestly and for a limited time. They are, even so, the best-evidenced medicines the class contains.

The cholinergic medicines treat the symptoms of Alzheimer's disease; they do nothing to its cause. The search for a medicine that would act on the cause has centered, for thirty years, on amyloid, the protein that forms the plaques found in the Alzheimer's brain. From that search came the anti-amyloid antibodies, laboratory-made antibodies that bind amyloid and prompt the brain to clear it.

Their arrival has been turbulent. The first, aducanumab, was approved by the United States Food and Drug Administration in 2021 over the near-unanimous objection of the agency's own advisory committee, several of whose members resigned; its benefit was, at best, unclear, and it was withdrawn by its maker in 2024.^[5] Two later antibodies rest on stronger trial evidence: lecanemab, approved in 2023,^[6] and donanemab, approved in 2024.^[7] Both clear amyloid from the brain, and both slow the decline of early Alzheimer's disease; but the slowing is modest, and it is bought at a real price. The antibodies cause a pattern of brain swelling and small hemorrhages, visible on imaging and known as ARIA, which is usually silent but can be serious and is occasionally fatal; the risk is concentrated in people who carry two copies of a particular high-risk variant of the APOE gene. Whether the modest benefit is worth the burden and the risk is genuinely debated, and recent systematic reviews have questioned whether the benefit is clinically meaningful at all.^[8]

Beyond the racetams and the medicines for dementia lies the largest and least regulated part of the class: the materials taken by healthy people in the hope of sharpening an ordinary mind. The best studied of them is not a nootropic in Giurgea's sense at all, but a wakefulness-promoting medicine, modafinil, approved for narcolepsy and related disorders of excessive sleepiness. It is estimated that the great majority of the modafinil taken worldwide is taken off-label, by people who are neither narcoleptic nor sleep-deprived, for its reputation as a "smart drug."^[9] The evidence for that reputation is genuinely mixed: modafinil appears to help most with complex tasks of executive function, and to help least, or not at all, with simple attention and with learning, and the studies do not agree among themselves. Adrafinil, a compound the body converts into modafinil, is sometimes used in its place.

A separate tradition produced the peptide nootropics. In the Soviet Union, and later in Russia, short synthetic peptides were developed as cognitive and protective medicines: semax, created in 1982 at the Institute of Molecular Genetics in Moscow as a fragment of the hormone ACTH altered to keep the cognitive action and shed the hormonal one, and the dipeptide noopept.^[10] Both are used as medicines in Russia and are almost unknown to regulators elsewhere.

Beyond all of these is the open marketplace of supplements sold as nootropics: amino acids and precursors such as 5-HTP, L-theanine, and melatonin; herbal extracts; and a steady churn of novel compounds. For most of this marketplace the evidence is thin, the regulation light, and the gap between the promise on the label and the demonstration in a trial very wide.

The nootropics and cognitive enhancers share a hoped-for effect, not a mechanism, and the mechanisms within the class are as varied as its membership. The cholinesterase inhibitors raise the level of acetylcholine by blocking the enzyme that destroys it. Memantine blocks the NMDA receptor. The anti-amyloid antibodies bind amyloid and prompt the brain to clear it. Modafinil promotes wakefulness through actions on several neurotransmitter systems that are still not fully mapped. The racetams, the founding members of the class, are the least understood of all: after sixty years their mechanism remains genuinely uncertain, attributed variously to effects on cell membranes, on the cholinergic system, and on the brain's energy metabolism, with no account established.

For the medicines whose targets are known, that a medicine engages its target is, as ever, better established than the full path from that engagement to a change in cognition. For much of the rest of the class even the target is unsettled, and the relationship between the material and any effect on a healthy mind remains, after all the years, a subject of research rather than a settled fact.

The safety of the class cannot be summarized in a sentence, because the class is too broad; the information for each medicine or material is best read on its own page. A few things can be said across it. Giurgea's original ideal placed low toxicity at the center of the definition, and the racetams and several of the supplement-grade materials do have a long record of few serious acute effects. That record does not extend to the whole class. The anti-amyloid antibodies carry a definite and sometimes serious hazard, the brain swelling and microhemorrhage called ARIA, which has to be watched for with repeated brain imaging. The cholinesterase inhibitors commonly cause nausea and other digestive effects and can slow the heart. And across the unregulated end of the class a different kind of risk applies: a supplement sold as a nootropic may not contain what its label claims, in the amount claimed, or anything active at all. Figures for these risks are population estimates that vary between studies, and individual response varies considerably from person to person.

This category collects the wiki's nootropic and cognitive-enhancer pages, a broad and loosely bounded class. They fall into several groups.

• The racetams, the family descended from piracetam: Piracetam, Aniracetam, Oxiracetam, Pramiracetam, Phenylpiracetam, and Coluracetam. These carry the Racetams subcategory.
• The peptide nootropics, short synthetic peptides developed chiefly in Russia: Noopept and Semax. These carry the Peptide Nootropics subcategory.
• The eugeroics, the wakefulness-promoting medicines used off-label for cognition, gathered in the Eugeroics subcategory; Adrafinil, a prodrug of modafinil, is indexed here directly.
• The anti-dementia medicines, the cholinesterase inhibitors, memantine, and the anti-amyloid antibodies, gathered in the Anti-Dementia Medicines subcategory; this is the one corner of the class with rigorous regulatory approval.
• The dietary precursors and cofactors: 5-HTP, L-Theanine, and Melatonin. These carry the Dietary Precursors and Cofactors subcategory.
• Bromantane, a Russian-developed compound that fits none of the groups above, is indexed here directly.

This category collects the nootropics and the cognitive enhancers: the medicines and other materials whose defining purpose, claimed or demonstrated, is to improve the workings of a mind. It is, by the nature of that definition, one of the broadest and least sharply bounded categories on the wiki, and its boundary is that purpose, not any shared chemistry, mechanism, or strength of evidence.

The class overlaps others, and its members are cross-indexed accordingly. The line between sharpening attention and stimulating the nervous system is one of degree, and several of the wakefulness-promoting materials gathered here are equally at home among the psychostimulants. The anti-dementia medicines belong as much to the broader pharmacy of neurology. The dietary precursors are cofactors and supplements before they are cognitive enhancers. Following the wiki's multi-membership convention, a material is indexed wherever its pharmacology and its uses warrant.

Each nootropic and cognitive enhancer indexed here has, or in time will have, its own page, built on the wiki's standard structure for a medicine: a history-first account, then pharmacology, indications where they exist, adverse effects, and interactions.

This is one of the wiki's MedCategory class-overview pages. It carries the MedCategory and MedCategoryFull marker tags; the second suppresses the member list that MediaWiki would otherwise generate automatically, leaving the curated index above as the one the reader sees. The category sits beneath Medicines and within the Pharmaceutical origin root, although, as the history above makes plain, a good deal of what the world calls a nootropic sits well outside the boundary of an approved medicine.